



**PHARMACY AND THERAPEUTICS COMMITTEE
ACA/Exchange MEETING MINUTES
August 28, 2025**

Attendance: Microsoft Teams Meeting
Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Rick Buzard, Associate Chief Medical Officer; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Sophie Cweiber, Pharmacy Student Intern; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Sharon Ford, Staff/Clinical Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Jessica (Tran) Hoang-Le, Staff/Clinical Pharmacist; Ruth John, Staff/Clinical Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Brandi Mahler, Supervisor Pharmacy Technicians; Lisa Murray, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Pablo Ramirez, Pharmacy Student Intern; Frances Fernandez Rivera, Pharmacy Student Intern; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Fallan Vaisberg, Formulary Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused: Dr. Paul Aitken, Medical Director; Dr. Demian Elder, Medical Director; Leah Finken, Clinical Programs Pharmacist; Samantha Jackson, Clinical Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Staff/Clinical Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the May 2025 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>

II. 2026 Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
Tier Changes (PID Objection Review)	The Committee reviewed the Tier Changes. The Committee approved as presented. • Betaine powder - Move to T4 • Deflazacort tablets and suspension - Move to T4 • Gemcitabine hcl 1 gm recon soln - Move to T4 • Gleostine capsules - Move to T3 • Irinotecan hcl solution - Move to T2 • Levorphanol tartrate tablets - Move to T4 • Oxaliplatin recon soln/solution - Move to T4 • Pemetrexed disodium recon soln - Move to T4 • Synarel 2 mg/mL solution - Move to T4 • Teriparatide 560 mcg/2.24mL soln pen - Move to T4	The Committee approved as presented.	H. McCaffrey	Resolved
2026 Brand Removals	The Committee reviewed the Brand Removals. • Aptiom • Brilinta • Promacta • Tasigna • Fycompa • Complera • Difucid • Entresto	The Committee approved as presented.	H. McCaffrey	Resolved
2025 and 2026 Formulary Additions	The Committee reviewed the 2025 and 2026 Formulary Additions. The Committee approved as presented. • Abigale 1-0.5 mg tab - T2 • Abigale lo 0.5-0.1 mg tab - T2 • Advanced eye relief 0.2 % solution - T2 • Eltrombopag olamine 12.5 mg packet - T5, PA, QL 360/30 • Eltrombopag olamine 12.5 mg tab - T5, PA, QL 30/30 • Eltrombopag olamine 25 mg packet - T5, PA, QL 180/30 • Eltrombopag olamine 25 mg tab - T5, PA, QL 30/30 • Eltrombopag olamine 50, 75 mg tab - T5, PA, QL 60/30 • Emtricitab-rilpivir-tenofovir df 200-25-300 mg tab - T2, QL 30/30 • Eslicarbazepine acetate 200, 400 mg tab - T4, QL 30/30, ST	The Committee approved as presented.	F. Vaisberg	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	• <i>Eslicarbazepine acetate 600, 800 mg tab - T4, QL 60/30, ST</i> • <i>Fidaxomicin 200 mg tab - T3, PA</i> • <i>Galbriela 0.8-25 mg-mcg chew tab - T0</i> • <i>Kerendia 40 mg tab - T4, PA, QL 30/30</i> • <i>Meleya 0.35 mg tab - T0</i> • <i>Miudella intrauterine copper iud - T0, QL 1/365</i> • <i>Naloxone hcl 0.4 mg/mL soln prsyr - T2</i> • <i>Nilotinib hcl 50, 150, 200 mg cap - T5, PA</i> • <i>Orquidea 0.35 mg tab - T0</i> • <i>Perampanel 2, 4, 6, 8, 10, 12 mg tab - T4, QL 30/30</i> • <i>Sacubitril-valsartan 24-26 mg, 49-51 mg, 97-103 mg tab - T2, QL 60/30</i> • <i>Ticagrelor 60 mg tab, 90 mg tab - T3</i> • <i>Tolvaptan 15 mg tab thpk - T4, PA</i> • <i>Tolvaptan 30 & 15, 45 & 15 mg, 60 & 30 mg tab thpk - T4, PA</i>			

III. Drug Formulary Review/Update

2025 and 2026 Prior Authorization Review	<i>The Committee reviewed the Prior Authorization criteria and approved as presented.</i> <i>No clinical updates:</i> • <i>Arcalyst</i> • <i>Austedo</i> • <i>Carglumic acid</i> • <i>Deferasirox</i> • <i>Deferiprone</i> • <i>Dihydroergotamine Nasal</i> • <i>Filgrastim Agents</i> • <i>Gattex</i> • <i>Icatibant</i> • <i>Ingrezza</i> • <i>Myalept</i> • <i>Regranex</i> • <i>Rufinamide</i> • <i>Sodium Phenylbutyrate</i> • <i>Tasimelteon</i> • <i>Teriparatide</i> • <i>Testosterone Replacement Therapy</i>	<i>The Committee reviewed the Prior Authorization criteria and approved as presented.</i>	<i>F. Vaisberg</i> <i>C. Chan</i> <i>G. Bledsoe</i> <i>J. Zubrzycki</i> <i>H. McCaffrey</i> <i>J. Crawford</i> <i>R. Spencer</i> <i>S. Ford</i> <i>Y. Hedrick</i> <i>M. Prokopets</i>	<i>Resolved</i>
---	--	---	--	-----------------

	• <i>Tetrabenazine</i> • <i>Topical retinoids</i> <i>Criteria updated:</i> • <i>Ventavis</i> • <i>Mavyret</i> • <i>Xermelo</i> • <i>Xifaxan 550mg</i> • <i>Acute Seizure Agents</i> • <i>Nucala</i> • <i>Xolair</i> • <i>Dupixent</i> • <i>Hemophilia Agents – Initial</i> • <i>Hemophilia Agents – Reauthorization</i> • <i>Adempas</i> • <i>Endothelin Receptor Antagonists</i> • <i>Ofev</i> • <i>Phosphodiesterase-5 Inhibitors PDE5I</i> • <i>Pirfenidone</i> • <i>Uptravi</i> • <i>Xdemvy</i> • <i>Kesimpta</i> • <i>Denosumab Products</i> • <i>Actimmune</i> • <i>Alpha-1 Proteinase Inhibitors</i> • <i>Epidiolex</i> • <i>Tadalafil for BPH (2.5 mg tablet and 5 mg tablet)</i> • <i>Revcovi</i> • <i>Eucrisa</i> • <i>Opipza Oral Film</i> • <i>Journavx</i> • <i>Apomorphine</i> • <i>Diacomit</i> • <i>Doptelet</i> • <i>Eltrombopag</i> • <i>Kerendia</i> • <i>Adalimumab</i> • <i>Enbrel</i> • <i>Rinvoq/Rinvoq LQ tablet/solution</i> • <i>Skyrizi</i> • <i>Xeljanz</i> • <i>Wegovy (Non-Formulary)</i>			
--	--	--	--	--


	• GLP-1 Agonists (Ozempic, Trulicity) • CGRP Antagonists			
IV. New Drug Review	<i>(Presented in New Drug Review for Medicare.) The following new products were reviewed and will be kept as non-formulary:</i> • Lynozyfic (linvoseltamab-gcpt) Injection* • Zegfrovy (sunvozertinib) Tablets* • Spritam (levetiracetam) Tablets for Oral Suspension • Breyanzi (lisocabtagene maraleucel) Suspension for Intravenous Infusion • Datroway (datopotamab deruxtecan-dlnk) Lyophilized Powder for Injection • Monjuvi (tafasitamab-cxix) for Injection • Yeztugo (lenacapavir) Tablets and Injection* • Keytruda (pembrolizumab) for Injection • Zusduri (mitomycin) for Intravesical Solution - formerly UGN-102* • Ibtrozi (taletrectinib) Capsules* • Brukinsa (zanubrutinib) Capsules and Tablets • Nubeqa (daraloutamid) Tablets • Zynyz (retifanlimab-dlwr) Injection • Welireg (belzutifan) Tablets • Emrelis (telisotuzumab vedotin-tllv) Lyophilized Powder for Injection* • Aymapki Fakzynja Co-Pack (avutometinib and defactinib, co-packaged) Capsules/Tablets* • Mezofo (aripiprazole) Oral Film* • Shingrix (zoster vaccine, recombinant, adjuvanted) Injection • Kerendia (finerenone) Tablets • Spikevax (Moderna COVID-19 Vaccine, mRNA) Injection • Gammagard Liquid (immune globulin infusion [human]) Solution • Benlysta (belimumab) Injection • Dupixent (dupilumab) Injection • mRESVIA (respiratory syncytial virus vaccine, mRNA) Injection • Mavyret (glecaprevir and pibrentasvir) Tablets and	<i>The Committee approved the New Drug Review as presented and recommended.</i>	<i>G. Ho</i>	<i>Resolved</i>

	<i>Oral Pellets</i> • <i>MNEXSPIKE (Covid-19 Vaccine, mRNA) Injection*</i> • <i>Hadlima (adalimumab-bwwd) Injection</i> • <i>Nuvaxovid (Covid-19 Vaccine, Adjuvanted) Injectable Suspension*</i> • <i>Rinvoq (upadacitinib) Extended-Release Tablets</i> • <i>Anzupgo (delgocitinib) Topical Cream*</i> • <i>Kirsty (insulin aspart-xjhz) Injection*</i> • <i>Ekterly (sebetrastat) Tablets*</i> • <i>Kisunla (donenemab-azbt) Injection</i> • <i>Gamifant (emapalumab-lzsg) Injection</i> • <i>Vizamyl (flutemetamol F 18) Injection</i> • <i>Neuraceq (florbetaben F18) Injection</i> • <i>Harliku (nitisinone) Tablets*</i> • <i>Endari (L-glutamine) Oral Powder</i> • <i>Andembry (garadacimab-gxii) Injection*</i> • <i>Arynta (lisdexamfetamine dimesylate) Oral Solution*</i> • <i>Steqeyma (ustekinumab-stba) Injection</i> • <i>Enflonsia (clesrovimab-cfor) Injection*</i> • <i>Widaplik (amlodipine, indapamide and telmisartan) Tablets*</i> • <i>Xifyrm (meloxicam) Injection*</i> • <i>Xenoview (Xenon Xe 129 hyperpolarize) Oral Inhalation</i> • <i>Tryptyr (aolctremone) Ophthalmic Solution*</i> • <i>Khindivi (hydrocortisone) Oral Solution*</i> • <i>Yutrepia (treprostinil) Inhalation Powder*</i> • <i>Zoryve (roflumilast) Cream and Foam</i> • <i>Starjemza (usetekinumab-hmny) Injection*</i> • <i>Nucala (mepolizumab) Injection</i> • <i>Susvimo (ranibizumab) Injection for Intravitreal Use via Ocular Implant</i> • <i>Yuflyma (adalimumab-aaty) Injection</i> • <i>Jivi (antihemophilic factor [recombinant] PEGylated-aucl) Injection</i> • <i>Brekiya (dihydroergotamine mesylate) Injection*</i> • <i>Otulfi (ustekinumab-aauz) Injection</i> • <i>Selarsdi (ustekinumab-aekn) Injection</i> • <i>Atzumi (dihydroergotamine mesylate) Nasal Powder*</i> • <i>Imaavy (nipocalimab-aahu) Injection*</i> • <i>Zevaskyn (prademagene zamikeracel) Gene-</i>			
--	--	--	--	--

	<i>Modified Cellular Sheets*</i> • <i>HemiClor (chlorthalidone) Tablets*</i> <i>(* Previously discussed in New Drug Review for Medicaid)</i>			
--	--	--	--	--

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held October 2025.



9/5/2025

Danielle Dolores, Director of Pharmacy Services

Date